Belimumab Market Trends and Future Insights Through 2030

Introduction to Benlysta (Belimumab) Benlysta (belimumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody engineered to inhibit B-lymphocyte stimulator (BLyS), a protein essential for B-cell survival. Approved for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, Benlysta has significantly advanced autoimmune

read more